Cooley Advises Kite Pharma on $146 Million Initial Public Offering

San Diego – July 1, 2014 – Cooley LLP announced today that it advised Kite Pharma, Inc. on its $146.6 million IPO. Kite Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The company now trades on The NASDAQ Global Select Market under the symbol "KITE."

The Cooley corporate securities team was comprised of partners Fred Muto (head of the firm's business department), Charlie Kim and Charles Bair, and associates Veer Bhavnagri, Kristin VanderPas, Rebecca Jones and Katherine Decker-Sadowski. Critical support for the offering was provided by partners Natasha Leskovsek and Wendy Goldstein, special counsel Phil Mitchell and associate Jennifer Shanley (health care and life sciences regulatory); special counsel Laura McDaniels (compensation and benefits); and partner Susan Philpot (tax).

Thus far in 2014, Cooley has advised on 62 completed public offerings, including 30 completed IPOs.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

Related Contacts
Susan Cooper Philpot Partner, San Francisco
Fred Muto Senior Counsel, San Diego
Charles Bair Partner, San Diego
Charlie Kim Partner, San Diego
Natasha Leskovsek Partner, Washington, DC
Laura McDaniels Special Counsel, Palo Alto
Kristin VanderPas Partner, San Francisco
Wendy Goldstein Partner, New York
Phil Mitchell Partner, New York